Citations

Clear

2391 citation(s) found for "Ma, Lin".

Thymomas and Thymic Carcinomas, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Riely, Gregory J. , Wood, Douglas E. , Aisner, Dara L. , Akerley, Wallace , Bauman, Jessica R. , DeCamp, Malcolm M., Desai, Aakash , Dilling, Thomas J. , Durm, Gregory A. , Gettinger, Scott , Gubens, Matthew A. , Lackner, Rudy P., Maldonado, Fabien , Morgensztern, Daniel , Mullikin, Trey C. , Ng, Thomas, Owen, Dawn , Patel, Sandip Pravin , Riess, Jonathan W. , Shapiro, Theresa A. , Singh, Aditi P. , Stevenson, James, Tam, Alda L. , Yang, Stephen C. , Yau, Edwin , Gregory, Kristina M., Hang, Lisa, Desai, Aakash P , Loo, Billy W. , Bharat, Ankit , Chang, Joe Y. , Chirieac, Lucian R. , Dowell, Jonathan E. , Grotz, Travis E. , Juloori, Aditya , Lanuti, Michael D. , Lin, Jules , Lovly, Christine Marie , Owen, Dwight H , Patil, Tejas , Polanco, Patricio Marcelo , Tanvetyanon, Tawee , Yanagawa, Jane

Mayo Clinic

Journal of the National Comprehensive Cancer Network | June 11, 2025 | Volume: 23 | Issue: 6 | Pages: 255-269

10.6004/jnccn.2025.0027 | PMID 40499586 Get It

Thymomas and thymic carcinomas are rare mediastinal tumors that originate in the thymus. Patients with thymoma may experience symptoms associated with autoimmune paraneoplastic diseases (such as myasthenia gravis), which typically do not occur in patients with thymic carcinoma. The NCCN Guidelines for Thymomas and Thymic Carcinomas provide guidance for the diagnosis, treatment, and surveillance of patients with thymoma and thymic carcinoma. Involvement of a multidisciplinary team with experience treating thymomas and thymic carcinomas is highly recommended.
l ‐Cysteine Alleviates Peritoneal Fibrosis by Repressing PKM2 in Peritoneal Mesothelial Cells
Ma, Xiaokun , Li, Yin , Huang, Yuebo , Sun, Yuxiang , Sha, Zixin , Lin, Hongchun, Shang, Hongli, Wu, Peizhi, Li, Canming , Ye, Zengchun , Peng, Hui , Peng, Hui , Li, Yongjie, Wei, Dandan, Hu, Cheng , Hu, Zhaoyong

Mayo Clinic

The FASEB Journal | June 11, 2025 | Volume: 39 | Issue: 11 | Pages: No page available

10.1096/fj.202500229r | PMID 40497367 Get It

ABSTRACT Peritoneal fibrosis is one of the main causes of peritoneal dysfunction and withdrawal of patients from peritoneal dialysis (PD). Our previous study has shown that high‐glucose dialysis solution promotes glycolysis in peritoneal mesothelial cells, leading to mesothelial‐to‐mesenchymal transition (MMT) and peritoneal fibrosis. However, the molecular mechanisms remain unclear. Using single‐cell RNA sequencing (scRNA‐seq) analysis of cells from the effluent of patients undergoing PD from our previous study, we found that pyruvate kinase isozymes M2 (PKM2), a key rate‐limiting enzyme of glucose metabolism, was significantly upregulated in the mesothelial cells of patients with long‐term peritoneal dialysis (LPD). Using co‐immunoprecipitation, chromatin immunoprecipitation assay, and gene silencing techniques, we revealed that PKM2 promotes the expression of transcription factor SNAI2 by acetylating histone H3K9 (H3K9ac), thereby promoting the occurrence of MMT and hence peritoneal fibrosis. l ‐cysteine, a known PKM2 inhibitor, blocked these responses and prevented PD‐induced peritoneal fibrosis. These results could provide a novel therapeutic strategy for treating peritoneal fibrosis.
Eliminating The Need for Sequential Confirmation of Response in Multiple Myeloma
Claveau, Jean‐Sébastien , Kapoor, Prashant , Binder, Moritz , Buadi, Francis K. , Dingli, David , Fonder, Amie , Gertz, Morie A. , Hayman, Suzanne R. , Hobbs, Miriam, Christenson, Lisa Hwa, Kourelis, Taxiarchis , Lacy, Martha Q. , Lin, Yi, Warsame, Rahma , Kyle, Robert A. , Kumar, Shaji , Buadi, Francis K , Dispenzieri, Angela , Fonder, Amie , Gertz, Morie A , Hwa Christenson, Yi Lisa, Kourelis, Taxiarchis , Lacy, Martha Q , Leung, Nelson , Warsame, Rahma , Kumar, Shaji K , Binder, Moritz , Dingli, David , Claveau, Jean-Sebastien , Dispenzieri, Angela , Gonsalves, Wilson I. , Christenson, Lisa Hwa, Leung, Nelson , Rajkumar, S. Vincent

Mayo Clinic

Blood Journal | June 9, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/blood.2024027949 | PMID 40489635 Get It

Disease response and progression assessment in multiple myeloma (MM) is based on various measurements of monoclonal protein (serum and urine protein electrophoresis, serum free light chain (FLC, and or quantitative immunoglobulins). Currently, the IMWG consensus response criteria require two sequential assessments of any one marker made at any time before confirmation of disease progression and the institution of any new therapy. However, this can be cumbersome in clinical trials. Herein, we hypothesized that if two markers meet the progression criteria simultaneously, a repeat of either will not be necessary for confirmation. We retrospectively studied all sequential patients with myeloma enrolled in clinical trials at Mayo Clinic. We identified 583 episodes of confirmed progression in our study. Among the 583 progression episodes, nearly 70% (sensitivity of the simultaneous criteria) met the two simultaneous variable criteria at the first testing, indicating progression. Conversely, among 413 patients who met progression criteria by two simultaneous values, 98% (specificity of the simultaneous criteria) of patients subsequently had confirmed progression by sequential values. In summary, for patients with two disease burden markers meeting the simultaneous progression criteria, sequential assessment either one for confirmation may not be necessary to determine disease progression.
Brain-derived extracellular vesicle microRNAs in Lewy body and Alzheimer’s disease
Yang, Stephanie , Lin, Andrew A. , Shen, Hanfei , Pappalardo, Laura W., Spychalski, Griffin B. , Forsberg, Leah K. , Grant, Kiera M., Savica, Rodolfo , Reichard, R. Ross , McLean, Pamela J. , Yang, Stephanie J , Jones, David T , Dickson, Dennis W , Reichard, R Ross , Nguyen, Aivi T , Boeve, Brad , McLean, Pamela J , Rosario, Jean G. , Forsberg, Leah K., Grant, Kiera M., Buser, Joshua R. , O’Bryant, Sid, Jones, David T., Dickson, Dennis W. , Nguyen, Aivi T. , Meaney, David F. , Boeve, Bradley F. , Issadore, David

Mayo Clinic

No container title available | June 9, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.06.06.656900 | PMID 40661348 Get It

Abstract INTRODUCTION Robust plasma-based biomarkers to distinguish Lewy body disease (LBD) and Alzheimer’s disease (AD) are currently lacking. We applied track-etch magnetic nanopore (TENPO) sorting for enrichment of brain-derived extracellular vesicle (EV) signatures as potential biomarkers to address this gap. METHODS We analyzed plasma from 137 autopsy-confirmed patients [30 LBD, 31 AD, 30 AD/LBD, 19 AD with amygdala Lewy bodies (AD/ALB), and 27 controls], sequencing miRNAs from TENPO-isolated GluR2-positive (neuron-enriched) and GLAST-positive (astrocyte-enriched) EVs, and measuring plasma proteins (Aβ40, Aβ42, tau, p-Tau181, p-Tau231) via SIMOA. RESULTS We identified 16 GluR2+, 8 GLAST+, and 4 protein biomarkers with differential expression (false discovery rate-corrected P value < .1) between LBD and AD. A multimodal 15-feature panel classified LBD versus AD with 10-fold cross-validated accuracy = 0.95 and area under the curve (AUC) = 0.96. DISCUSSION Brain-derived EVs offer accurate and accessible miRNA biomarkers for the differential diagnosis of LBD and AD.
A Radiomic Approach to Clinical MRI Refines the Thalamus-Cognition Link in Multiple Sclerosis
Davis, Levi, Orellana, Renán A., Sun, Rongyi , Özçelik, Sinem , Isenstein, Nina M., Onomichi, Kaho, Iqbal, Rifat, Zhao, B., Zeydan, Burcu , Kantarci, Orhun H. , Jager, Philip L. De , Riley, Claire , De Jager, Philip L , Zeydan, Burcu , Buyukturkoglu, Korhan , Lin, Lu , Davis, Levi, Orellana, Renan E., Iqbal, Rifat, Stern, Yaakov, Riley, Claire

Mayo Clinic

No container title available | June 9, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.06.05.657698 | PMID 40661563 Get It

Abstract Background and Objectives Radiomics extracts imaging features that may not be detectable through conventional volumetric analyses. Given their role in multiple sclerosis (MS), we applied radiomics to thalamic nuclei and examined their associations with cognitive performance. Methods A total of 601 individuals were included (342 people with MS-PwMS from two cohorts, and 259 healthy controls-HC). Radiomic features (RF) and volumes were extracted from the whole thalamus, five thalamic nuclei, and the putamen segmented on 3D T1-weighted images. Cognitive performance was assessed using the Symbol Digit Modalities Test (SDMT) and Paced Auditory Serial Addition Test (PASAT) in PwMS, and the Digit Symbol Substitution Test (DSST) in HC. In the first MS cohort, multivariate linear regression in a discovery set (N=103) identified thalamus-derived RF associated with SDMT, which were retested in a replication set (N=63). Their associations with PASAT in a second MS cohort (N=176) and DSST in HC were also evaluated. We then tested whether the same RF, when extracted from the putamen, were associated with SDMT. LASSO models assessed the combined predictive value of RF and volumes. Figure 2 presents an overview of the involvement of different cohorts in the study, outlining the specific study objectives and the statistical analysis approaches employed. Results Twenty-eight RF–ROI pairs were associated with SDMT in the replication set (FDR<0.05). Of these, 24 were also associated with PASAT (FDR≤0.03), and 2 with DSST. Only ventral nuclei volume showed replicated associations among volumetrics. Only 4 putamen-derived pairs were associated with SDMT (FDR=0.04). LASSO results confirmed RF outperformed volumes. Discussion RF extracted from the thalamus are strongly associated with cognitive performance in PwMS, outperforming volumetric measures and supporting their potential as sensitive imaging biomarkers.
First-line encorafenib + cetuximab + mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancer (BREAKWATER): Progression-free survival and updated overall survival analyses.
Élez, Elena , Shen, Lin , Kim, Tae Won, Yaeger, Rona , Usari, Tiziana, Laliberte, Robert J, Dychter, Samuel S., Zhang, Xiaosong , Yoshino, Takayuki , Lonardi, Sara , Cutsem, Eric Van , Eng, Cathy , Kim, Tae Won, Wasan, Harpreet , Desai, Jayesh , Ciardiello, Fortunato , Maughan, Tim , Morris, Van K. , Wu, Christina N. , Tabernero, Josep , Kopetz, Scott

Mayo Clinic

Journal of Clinical Oncology | June 4, 2025 | Volume: 43 | Issue: 17_suppl | Pages: No page available

10.1200/jco.2025.43.17_suppl.lba3500 Get It

LBA3500 Background: BREAKWATER (NCT04607421) is an open-label, global, randomized, phase 3 study evaluating first-line (1L) encorafenib + cetuximab (EC) ± chemotherapy (chemo) vs standard of care (SOC; chemo ± bevacizumab) in BRAF V600E-mutant metastatic colorectal cancer (mCRC). The study previously met one of its dual primary endpoints (EPs) demonstrating clinically meaningful and statistically significant improvement in confirmed objective response rate (ORR) by blinded independent central review (BICR) in the ORR subset. These results were the basis for the FDA accelerated approval of EC+mFOLFOX6 for BRAF V600E-mutant mCRC, including in the 1L, under Project Frontrunner. Here, we report the primary analysis of progression-free survival (PFS) by BICR, updated interim analysis of OS, updated safety, and other analyses. Methods: Eligible patients (pts) with untreated BRAF V600E-mutant mCRC were randomized 1:1:1 to receive EC, EC+mFOLFOX6, or SOC; EC arm enrollment was closed after a protocol amendment. Dual primary EPs: ORR and PFS by BICR (EC+mFOLFOX6 vs SOC); key secondary EP: OS (EC+mFOLFOX6 vs SOC). Results: 637 pts were randomized to EC, EC+mFOLFOX6, or SOC. Baseline demographics and disease characteristics were generally balanced between arms. EC+mFOLFOX6 (data cutoff: Jan 6, 2025) demonstrated a clinically meaningful and statistically significant PFS improvement vs SOC, meeting the other dual primary EP; HR=0.53 (95% CI 0.407, 0.677; P<0.0001); median PFS 12.8 vs 7.1 mo. OS was clinically meaningful and statistically significant vs SOC; HR=0.49 (95% CI 0.375, 0.632; P<0.0001); median OS 30.3 vs 15.1 mo. Median PFS and OS in the EC arm were 6.8 and 19.5 mo. These data and response data for all randomized pts are shown in the table. Serious treatment-emergent adverse events occurred in 30%, 46%, and 39% of pts in the safety analysis set. Safety was consistent with that known for each agent. Conclusions: BREAKWATER demonstrated clinically meaningful and statistically significant PFS and OS improvements with EC+mFOLFOX6 vs SOC and manageable toxicities. EC+mFOLFOX6 is potentially practice changing as the new SOC. Clinical trial information: NCT04607421 . ECn=158 EC+mFOLFOX6n=236 SOCn=243 EC+mFOLFOX6vs SOCHR (95% CI)P-value a Median PFS b , mo (95% CI) 6.8(5.7, 8.3) 12.8(11.2, 15.9) 7.1(6.8, 8.5) 0.53 (0.407, 0.677) <0.0001 Median OS, mo (95% CI) 19.5(17.6, 22.5) 30.3(21.7, NE) 15.1(13.7, 17.7) 0.49 (0.375, 0.632)<0.0001 ORR, b % (95% CI) 45.6(38.0, 53.3) 65.7(59.4, 71.4) 37.4(31.6, 43.7) Median DOR b , mo (95% CI) c 7.0 (4.2, 11.6) 13.9 (10.9, 18.5) 10.8 (7.6, 13.4) DOR b ≥6 mo, n (%) c 29 (40.3) 110 (71.0) 38 (41.8) DOR b ≥12 mo, n (%) c 15 (20.8) 54 (34.8) 16 (17.6) Median time to response, b wk (range) c 6.6(4.3-86.4) 7.0(5.1-103.6) 7.3 (5.4-48.0) a 1-sided stratified log rank test. b By BICR. c Responders: n=72, n=155, and n=91. DOR, duration of response.
Novel mouse model reveals neurodevelopmental origin of PMM2-CDG brain pathology
Edmondson, Andrew C. , Xia, Zijie , Melendez-Perez, Ashley, Cai, Cadmus, Collins, Ashley M., Shiplett, Emily J. , Hill, Sophie F. , Somarowthu, Ala , Dam, Jacques Van, Pai, Ling-Lin, Santi, Mariarita , He, Miao , Radenkovic, Silvia , Hill, Sophie F , Edmondson, Andrew C , Budhraja, Rohit , Xia, Zijie, Melendez-Perez, Ashley J. , Cai, Cadmus, Dam, Johanna, Kim, Seonhee , He, Miao, Goldberg, Ethan M. , Kozicz, Tamás , Morava, Éva , Pandey, Akhilesh , Zhou, Zhaolan

Mayo Clinic

No container title available | June 4, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.06.01.657261 | PMID 40501776 Get It

Abstract Congenital disorders of glycosylation (CDG) are a group of neurogenetic conditions resulting from disruptions in the cellular glycosylation machinery. The majority of CDG patients have compound heterozygous pathogenic variants in the phosphomannomutase 2 ( PMM2) gene. Individuals with PMM2-CDG exhibit multi-systemic symptoms, prominently featuring neurological deficits with nearly all patients exhibiting cerebellar hypoplasia and ataxia. To overcome embryonic lethality caused by whole body knock-out of Pmm2 and mimic patient-related compound heterozygous pathogenic variants, we paired a Pmm2 flox allele ( Pmm2 fl ) with a catalytically inactive knock-in allele ( Pmm2 R137H ), commonly present in PMM2-CDG patients. Mice with post-mitotic loss of PMM2 from neurons or astrocytes are indistinguishable from unaffected littermates, including in a broad battery of neurological assessments. In contrast, removal of PMM2 from embryonic neural precursor cells leads to cerebellar hypoplasia, ataxia, seizures, and early lethality. Comprehensive multi-omics profiling, including metabolomics, glycomics, single-cell transcriptomics, proteomics, and glycoproteomics, reveal widespread molecular disturbances throughout the brain, with the cerebellum showing the most pronounced disruption. These findings highlight the heightened dependency of the developing cerebellum on intact N-glycosylation, aligning with clinical observations in PMM2-CDG patients. Importantly, glycoproteomic alterations identified in our mouse model are corroborated in PMM2-CDG patient post-mortem cerebellar tissue, underscoring the translational relevance of our findings and implicating impaired synaptic transmission as a key pathogenic mechanism.
Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma
Jagannath, Sundar , Martin, Thomas G. , Lin, Yi , Cohen, Adam D. , Raje, Noopur , Htut, Myo, Deol, Abhinav , Agha, Mounzer , Berdeja, Jesús G. , Liegel, Jessica J., Dhakal, Binod , Parekh, Samir , de, Rocío Montes , Plaks, Vicki , Sun, Huabin, Banerjee, Arnob , Schecter, Jordan M. , Lendvai, Nikoletta , Lengil, Tamar, Zhu, Jieqing, Koneru, Mythili, Akram, Muhammad, Patel, Nitin , Filho, Octavio Costa, Voorhees, Peter M. , Liegel, Jessica J , Rossi, Adriana , Lieberman-Cribbin, Alex , Usmani, Saad , Dhakal, Binod , Parekh, Samir , Montes de Oca, Rocio , Jakubowiak, Andrzej , Voorhees, Peter , Cohen, Adam D , Jagannath, Sundar , Lin, Yi , Berdeja, Jesús G , Raje, Noopur S , Htut, Myo , Lesokhin, Alexander M. , Rossi, Adriana , Usmani, Saad Z. , Li, Hui, Wang, Rui , Madduri, Deepu , Jakubowiak, Andrzej

Mayo Clinic

Journal of Clinical Oncology | June 3, 2025 | Volume: 43 | Issue: 25 | Pages: 2766-2771

10.1200/jco-25-00760 | PMID 40459151 Get It

CARTITUDE-1 evaluated ciltacabtagene autoleucel (cilta-cel) in patients with heavily pretreated relapsed/refractory multiple myeloma (RRMM). We describe overall survival (OS), ≥5-year progression-free outcomes, associated biomarkers, and safety, with a median study follow-up of 61.3 months. For the 97 treated patients, median OS was 60.7 months (95% CI, 41.9 to not estimable). One third (32/97) of patients remain alive and progression-free for ≥5 years after a single cilta-cel infusion, without maintenance treatment. Twelve of these patients treated at a single center underwent serial minimal residual disease (MRD) and positron emission tomography-computed tomography assessments, and all (100%) were MRD-negative (at least 10 −5 threshold) and imaging-negative at year 5 or later after cilta-cel. Baseline characteristics, including the presence of high-risk cytogenetics and extramedullary disease, were generally comparable for the 32 patients who were progression-free for ≥5 years versus patients who had progressive disease by year 5. A trend of lower baseline tumor burden, higher fraction of naïve T-cells in the cilta-cel drug product, higher T cell-to-neutrophil ratio, higher hemoglobin and platelets at baseline, and higher effector-to-target ratio were associated with ≥5-year progression-free status. The safety profile of cilta-cel remained consistent with previous reports. To our knowledge, our data provide the first evidence that cilta-cel is potentially curative in patients with RRMM.